Phase A — Understand the business
Lens 1 · Company Overview
What it is now. Upexi, Inc. (Delaware; originally Nevada, formed 2018; formerly "Grove, Inc.") describes itself in its own MD&A as "a digital asset treasury company focused on acquiring, holding, and deploying Solana ('SOL') as a core treasury asset." The legacy identity — "a brand owner specializing in the development, manufacturing, and distribution of consumer products" — is now a secondary clause. HQ: 3030 N. Rocky Point Drive, Tampa, FL.
How it actually makes money — two engines, wildly mismatched in size:
-
The SOL treasury (the real business). Buy SOL (liquid + discounted "locked" SOL), stake ~95% of it for yield, and grow "SOL per share" via accretive capital issuance. As of 2026-03-31 it held ~2,361,931 SOL at a fair value of $184,902,888 (cumulative purchases of $266,849,664 over the FY26 nine months at a blended cost ~$151–160/SOL). "Digital asset revenue" (staking rewards) was $3.51M in Q3 and $14.73M for the nine months — but this is non-cash crypto recognized at receipt, not a cash margin.
-
The consumer-products remnant (being euthanized). Legacy brands run through subsidiaries — MW Products, LuckyTail (pet), HAVZ/Steam Wholesale (health & wellness incl. hemp), Cygnet (Amazon), Upexi Distribution. Product revenue fell 66.8% YoY in Q3 to $1,050,667 and 38.2% for the nine months to $7,115,322. In December 2025 management resolved to shut down the hemp/CBD manufacturing and distribution operations (completed Feb 2026); as of 2026-06-01 the company "will no longer lease warehouse space, with all brand distribution activities to be handled by third-party providers." The company had 10 full-time employees as of 2026-04-01.
Customers / suppliers / competitors. For the products remnant: US-centric (US revenue $997K of $1,051K in Q3), Amazon + DTC + wholesale, contract-manufactured. For the treasury: the relevant "suppliers" are the custodians (BitGo Trust as primary, Coinbase secondary), the lender (BitGo Prime), the validators Upexi stakes with, and the convertible-note holders who supplied SOL. The competitive set is the cohort of SOL treasury companies — DeFi Development Corp (DFDV), Sol Strategies, Sharps Technology, BIT Mining — plus the archetype, Strategy/MicroStrategy in BTC.
Contract structure / key terms. No take-or-pay; product revenue is point-of-sale on shipment. The economically decisive "contracts" are the convertible notes and the BitGo credit facility (Lens 9/10/13). Critically, single reporting segment — management explicitly reports one segment (branded products) post the E-Core sale, with the treasury folded in.
Lens 2 · Supply Chain
For a DAT the "supply chain" is the SOL acquisition-custody-staking-financing loop. Named stakeholders along the chain:
- Capital in → Equity buyers (April 2025 PIPE at $2.28; July/Nov/Feb private placements; ATM program) and convertible-note investors who contributed SOL in kind (July 2025 issuance ~$151.2M; Jan 2026 issuance ~$36.0M). GSR Growth Investments LP (a related party of the former asset manager) held ~7.45% of shares.
- SOL acquisition → Liquid bulk/VWAP/TWAP purchases on exchanges, plus direct negotiation for "locked" SOL at a discount to spot (marked at a 14% discount to month-end price).
- Custody → BitGo Trust Company (South Dakota; primary; $250M insurance policy) and Coinbase, Inc. (secondary; $250K cash insurance). >98% of SOL in cold storage; key-generation ceremonies on offline devices.
- Yield → Native staking to multiple third-party Solana validators (~95% of treasury staked), ~7% target yield, two-day unbonding.
- Leverage → BitGo Prime, LLC Master Loan Agreement — borrow up to >$71M for SOL purchases at 11.50%, collateralized by treasury assets, 260% initial collateral level / 175% margin-call level. Outstanding $57,295,723 at 2026-03-31 (was $20M at 6/30/25).
- Pricing oracle → CoinMarketCap close prices (declared the "principal market" for ASC 820 Level 1).
Chokepoints / single-source dependencies (this is the whole risk map):
- One asset. "Our treasury is exclusively dedicated to the SOL digital asset." No hedging — "We do not hedge our SOL and do not have plans to hedge." 100% idiosyncratic SOL exposure, levered.
- The 175% margin-call trip-wire on the BitGo facility. A SOL drawdown that pushes collateral coverage toward 175% forces SOL sales into weakness.
- SOL-repayable debt. The converts, if not converted, "will settle the obligation through the return of the digital assets originally received" — i.e., ~1.23M SOL is owed back to bondholders in kind.
Lens 3 · Competitive Advantages (moats)
Bluntly: there is no operating moat, and there is barely a financial one. A DAT's only durable edge is the ability to issue equity above net asset value and compound "tokens per share" — a moat made entirely of investor confidence + cost of capital. Upexi has lost that edge:
- mNAV < 1x. At 2025-10-31 Upexi traded at 0.7x basic mNAV (1.3x fully-loaded). When a DAT trades below NAV, issuing equity is dilutive to tokens-per-share — the flywheel runs in reverse. DFDV, the larger SOL peer, hit the same wall ("inverted mNAV at 0.6x has prevented [it] from purchasing new SOL"). This is the single most important structural fact: the accretion engine is off.
- No brand / switching-cost / network moat on the products side — commoditized Amazon/DTC consumables being wound down.
- The one residual edge: access to discounted locked SOL via direct negotiation (built-in gain as the 14% discount accretes to par) and ~7% staking yield. Real but small, and swamped by mark-to-market and interest expense.
- Bargaining power: weak in every direction. Upexi needs its lender (BitGo), its custodians, and its capital-market financiers far more than they need Upexi. The convertible-note holders dictated SOL-settlement terms; the former asset manager (GSR) extracted a 20-year, 5x-or-$15M-termination-fee contract (Lens 9).
Verdict on moat: none on operations; the financial "moat" (issue-above-NAV compounding) has inverted into a liability. What's left is a fund that is structurally a price-taker on its single asset.
Lens 4 · Segments
segments.csv is empty; management reports a single segment and explicitly disaggregates only by geography and product source (digital-asset revenue excluded from that table).
Revenue disaggregation, nine months ended 2026-03-31 vs 2025:
| Line | 9M FY26 | 9M FY25 | Δ |
|---|
| Product revenue — US | $6,950,947 | $11,344,823 | −38.7% |
| Product revenue — Other | $164,375 | $177,664 | −7.5% |
| Product revenue total | $7,115,322 | $11,522,487 | −38.2% |
| Digital asset (staking) revenue | $14,733,562 | $0 | n/m |
| Total revenue | $21,848,884 | $11,522,487 | +89.6% |
By product source (9M): internally manufactured $4.51M (collapsing as manufacturing exits), contract-manufactured $2.52M, finished-goods $0.08M.
Trend & cause: product revenue is in managed decline (deliberate exit of hemp/wellness lines + warehouse closure). "Digital asset revenue" now exceeds product revenue 2:1, but it is non-cash staking recognized at fair value on receipt and then immediately exposed to SOL price moves (the realized/unrealized losses below). The "revenue grew 90%" headline is an artifact of mixing a non-cash crypto line into a shrinking products P&L. The honest read: the only segment that matters is the SOL balance sheet, and it is not on the revenue statement — it's the $185M of digital assets and the mark-to-market line.
Phase B — Measure performance
Lens 5 · Earnings Result (Q3 FY2026, period ended 2026-03-31)
The print is dominated by one number: a $92.3M unrealized loss on digital assets in the quarter ($178.8M for the nine months) as SOL fell.
Income statement, three months ended 2026-03-31:
| Line | Q3 FY26 | Q3 FY25 |
|---|
| Product revenue | $1,050,667 | $3,160,480 |
| Digital asset revenue | $3,506,432 | $0 |
| Total revenue | $4,557,099 | $3,160,480 |
| Gross profit | $4,350,734 | $1,559,106 |
| G&A | $4,931,678 | $2,642,654 |
| Stock-based comp | $3,987,514 | $521,353 |
| Unrealized loss on digital assets | $92,307,488 | $5,268 |
| Realized loss on digital-asset conversion to USD | $1,887,472 | $0 |
| Realized loss on sale of digital assets | $6,773,418 | $0 |
| Loss from operations | $(106,786,267) | $(3,587,233) |
| Interest expense, net | $(3,683,334) | $(245,103) |
| Net loss | $(109,343,830) | $(3,831,660) |
| Loss per share (basic & diluted) | $(1.67) | $(2.87) |
- vs. consensus: no meaningful sell-side consensus exists for a $64M-cap micro-cap DAT; "beat/miss" is not a useful frame. The market reaction to the May 12, 2026 release was muted — the stock was already ~$0.90 and the SOL drawdown was public.
- What drove it: 100% the SOL mark. Product gross margin optically rose to 80.4% (Q3) purely because manufacturing was eliminated; on a 9-month basis margin was flat at ~64.8%.
- Cash burn: operating cash flow −$17.2M (9M); the company financed itself with $67.5M of equity issuance and net SOL-collateralized debt.
- Balance-sheet flags (severe):
- Total stockholders' equity is NEGATIVE: −$51,918,186 at 2026-03-31 (was +$90.1M at 6/30/25).
- Accumulated deficit $(282,064,460) — driven by the $178.8M SOL loss + heavy SBC.
- Cash just $3,482,847.
- Convertible notes payable $181,031,073 + short-term BitGo treasury debt $57,295,723 = ~$238M of debt against a $184.9M treasury and $3.5M cash.
- Guidance: management explicitly guides product revenue down ("we do not expect significant increases to these revenue sources in future periods") and frames the future entirely around the treasury and a January-2026 "high-return treasury strategy."
The unusual-vs-history flag: management's own disclosure controls were concluded NOT effective, with two material weaknesses (inadequate segregation of duties; lack of multiple levels of supervision/review), unremediated as of the filing. For a company whose entire balance sheet is a single volatile asset valued off a third-party oracle, that is a non-trivial control gap.
Lens 6 · Earnings Calls (sentiment trend)
transcripts/ is empty (transcripts=0). From the web record:
- The Q3 FY26 call (May 14, 2026) framed the quarter around "revenue growth driven by digital asset treasury despite a challenging crypto market," the 9% QoQ SOL-count growth, ~2.5M shares bought back, "cost reductions," and the pivot to a higher-yield treasury strategy.
- Tone shift over the year: the FY2025 framing (mid-2025) was aggressive accumulation + "SOL per share" growth (PRs touting "+129% adjusted SOL per share," "$447M treasury," "2M SOL milestone"). By Jan 2026 the language shifted to "risk-adjusted high-yield" and "disciplined and prudent" — a defensive pivot toward squeezing yield because the issue-above-NAV accretion engine had stalled (mNAV < 1x). By May 2026 the emphasis moved to buybacks and cost cuts — the vocabulary of a company defending a depressed equity, not compounding one.
- Recurring phrase Upexi leans on: "adjusted SOL per share" — a company-defined non-GAAP metric that "adjusts for items… like investment timing and leverage." Treat with skepticism (Lens 13): a metric that adjusts out leverage on a levered vehicle is marketing, not measurement.
Lens 7 · Comps
For a DAT, P/E and EV/EBITDA are meaningless (no earnings, negative book equity). The right comp axis is mNAV (price vs. token NAV) and tokens-per-share trajectory across the SOL-treasury cohort.
| Company | Ticker | ~SOL held | ~Treasury value | mNAV | Note |
|---|
| Upexi | UPXI | ~2.0–2.36M | ~$165M @ SOL ~$73; $184.9M @ 3/31 | 0.7x basic / 1.3x loaded (2025-10-31) | ~$64M equity cap; negative book equity |
| DeFi Development Corp | DFDV | 2,223,074 | ~$160M | ~0.6x | Largest public SOL holder; 853% 2025 stock return then de-rated; $100M buyback |
| Sol Strategies | (CSE/Nasdaq) | n/a this run | n/a | n/a | SOL-native validator + treasury |
| Sharps Technology | STSS | ~2M SOL staked (95%) | n/a | n/a | Late entrant SOL DAT |
| BIT Mining | BTCM | "nearly doubled" SOL | n/a | n/a | Pivoting miner |
| Strategy (archetype) | MSTR | (BTC, not SOL) | n/a | historically >1x, premium-funded | The model Upexi explicitly imitates |
Comp read: Upexi is the smaller, more levered, lower-quality member of the SOL-DAT cohort. DFDV is larger, was the 853% 2025 darling, and still de-rated below NAV. The cohort-wide signal — multiple SOL DATs now trade at 0.6–0.7x NAV — tells you the market has stopped paying a premium for "levered SOL in a wrapper" and is now applying a conglomerate/leverage discount. Upexi's negative book equity and SOL-repayable debt put it at the bottom of the quality stack. n/a where peer multiples weren't sourceable this run.
Lens 8 · Stock-Price Catalysts
What moves UPXI >5% (mostly `` + the filing record):
- SOL price — the dominant driver. UPXI is a high-beta levered proxy for SOL. SOL fell from ~$293 (Jan 2025 peak) → ~$155 (June 2025) → ~$73 (June 2026), and UPXI fell from a post-PIPE high to ~$0.91.
- Treasury/capital-raise announcements — the July 2025 $150M convert + PIPE (the "doubling to 1.65M SOL" event) was the launch catalyst. Each subsequent dilutive raise is now a negative catalyst (issuing below NAV).
- The 1-for-20 reverse split (effective 2024-10-03) — a classic micro-cap survival move; pre-split share counts make the historical "per share" data noisy.
- GSR break-up (Oct–Dec 2025) — the public default-allegation exchange and arbitration with its own asset manager.
- "Adjusted SOL per share" PRs — management-driven upward catalysts in 2025 that faded as mNAV inverted.
What the pattern reveals: the market trades UPXI as leveraged SOL with a governance discount — it reacts to the token and to dilution/credit events, essentially not at all to the products business.
Phase C — Judge people & books
Lens 9 · Management
Allan Marshall — CEO & Chairman (age 58, CEO since May 2019).
- Track record (genuine): founded Segmentz, Inc. (2000), which through acquisitions became the infrastructure of XPO Logistics (NYSE: XPO) — a real, large-cap outcome. Serial development-stage entrepreneur. This is the bull pillar on management: he has built something big before.
- Skin in the game / control: holds 150,000 Series A preferred shares with 10 votes/share (super-voting), convertible to 138,889 common — i.e., entrenched voting control disproportionate to economics.
- Capital allocation on his watch: the defining decision was converting a small consumer-products roll-up into a single-asset levered crypto fund at a SOL cost basis of ~$151–160 — i.e., near the cycle high, funded with SOL-repayable debt. SOL is now ~$73. That is, to date, value-destructive capital allocation of the first order (accumulated deficit $282M; equity negative).
- Red flags — an unusually dense related-party web:
- Bought VitaMedica from his own company (he was one of three buyers of a subsidiary Upexi sold for $6.0M; purchase-price receivable still $1.34M outstanding).
- Leases a warehouse to Upexi through MFA 2510 Merchant LLC ($20,060/mo), which Upexi then spent $611,768 improving — and has now exited.
- $1.5M related-party promissory note (8.5% + 3.5% PIK) and a $400K advance settled by issuing himself the super-voting preferred at $2.60.
- New (Sept 2025) employment agreement: $840,000 base + performance bonuses tied to market cap / treasury growth — a comp design that rewards accumulating SOL and issuing stock even when that dilutes holders below NAV.
Andrew Norstrud — CFO & Director (age 51). Long-tenured (since 2019/2020), CPA, ex-Grant Thornton/PwC, prior CFO roles (GEE Group, Jagged Peak, Segmentz). Credible finance background — but presiding over a P&L with two unremediated material weaknesses.
Brian Rudick — Chief Strategy Officer (joined May 2025). The tell. He came directly from GSR ("Head of Research for GSR, the largest digital asset market maker… led GSR's lead investment into Upexi's $100M private placement") and previously ran a long-short bank book at Citadel, Balyasny, Millennium. So the same firm (GSR) (a) led the PIPE, (b) became the 20-year asset manager, (c) seeded Upexi's CSO — and then the relationship detonated into arbitration within ~8 months (Lens 10/13). The interlock is the story.
Gene Salkind, M.D. — Director, >10% holder. Neurosurgeon and prominent biotech investor (early Pharmacyclics, Intuitive Surgical). Audit-committee member; brings capital and name but no crypto/operating expertise.
Archetype: founder-controlled, promotional, capital-markets-driven micro-cap operator who pivoted hard into a narrative trade. The XPO pedigree is real; the governance hygiene is poor; the pivot was mistimed.
Lens 10 · Forensic Red Flags
Acting as a forensic analyst. This balance sheet is a minefield — most of it self-disclosed:
- Negative stockholders' equity (−$51.9M). The equity cushion is gone; further SOL declines push book equity more deeply negative.
- Debt > assets-that-matter. ~$238M debt (converts $181M + BitGo $57M) vs. $184.9M treasury + $3.5M cash. The converts are SOL-repayable (~962,955 SOL for the July-2025 note + 265,500 SOL for the Jan-2026 note ≈ 1.23M SOL, ~52% of the treasury, spoken for by bondholders).
- Material weaknesses in internal control over financial reporting — disclosure controls "not effective," unremediated.
- The "locked SOL" 14% discount is a management estimate (Level 2 input). ~978,852 of ~2.36M tokens are locked and valued at $71.47 (a 14% haircut to the $83.11 liquid price at 3/31). Management "monitors and adjusts" this discount — a subjective valuation lever on ~40% of the treasury.
- Massive, dilutive stock-based comp: $18.0M SBC over 9M (vs. $0.70M prior year), including $13.2M of RSUs and a $4.7M write-off of warrants granted to the (now-terminated) asset manager. On a company with $7M of product revenue, SBC is ~2.5x revenue.
- The Phantom Stock Appreciation Plan — 3,473,000 cash-settled PSUs, a liability remeasured each period; a cash drain if the stock recovers, dilutive in spirit if it doesn't.
- Deferred tax asset of $5.95M retained while booking a $282M deficit — management asserts "more likely than not… future taxable income," a notably optimistic going-forward judgment for a company in this state (partial $10.1M valuation allowance taken).
- Cash flow vs. earnings: the $221.5M net loss is ~80% non-cash (SOL marks + SBC), so the income statement overstates the cash problem — but operating cash burn is still −$17.2M/9M against $3.5M cash, so the company is structurally dependent on continuous capital-market access (ATM raised another ~$4.5M in Apr–May 2026).
- Reverse-split dilution litigation — the company itself sued in D. Nevada over 202,183 round-up shares from the 1-for-20 split that were issued then returned; residual dilution risk acknowledged.
Regulatory findings (required sub-section).
- SEC enforcement: No Litigation Releases and no AAERs name Upexi (or predecessor "Grove, Inc.") in the EDGAR EFTS search window 2021-06-24 → 2026-06-24.
- Item 1 Legal Proceedings (10-Q), quoted/summarized:
- Upexi v. GSR Strategies LLC (AAA arbitration, filed 2025-11-26) — Upexi seeks to void the Asset Management Agreement ab initio; GSR has filed counterclaims for damages + indemnification. Material, ongoing.
- Bloomios / Infusionz et al. v. Upexi (& predecessor Grove) (filed ~Apr 2025) — fraud/misrepresentation/breach claims from the 2022 Infusionz sale; Upexi calls it "baseless," won dismissal of individual directors, and counterclaimed for ~$19.5M allegedly owed.
- MVW Holdings v. E-Core (Upexi named) — trade-dress, fact-discovery phase.
- Eric Hanig v. Upexi / Cygnet Online — alleged $300K unpaid under a letter agreement; Upexi counterclaims fraud.
- Non-SEC enforcement (web search): no material FTC/DOJ/FDA/CFPB enforcement actions, consent decrees, or fines surfaced for "Upexi."
- Net: No securities-fraud enforcement on record, but an active, material arbitration with its own former asset manager and a cluster of commercial litigation typical of an acquisitive micro-cap. The control-environment weakness amplifies the concern.
Phase D — Project & stress-test
Lens 11 · Forward Projection
EPS forecasting is the wrong tool — Upexi has no earnings power independent of SOL marks. The decision variable is NAV-per-share / equity value as a function of SOL price, net of SOL-repayable debt. I model NAV, not EPS, with every input labeled `` off filing actuals. No forecast.ts create (watchlist rule).
Inputs: ~2.36M SOL (1.383M liquid + 0.979M locked); debt ~$238M of which ~$181M converts are SOL-repayable (~1.23M SOL) and ~$57M BitGo is USD/SOL-collateralized at 11.5%; cash ~$3.5M; ~70.3M shares (66.9M issued at 3/31 + ATM since); converts struck $4.25 / $2.39.
Treasury-value-to-equity bridge at three SOL prices:
| SOL price | Gross treasury (2.36M SOL) | Less BitGo debt (~$57M) | Less converts (~$181M, SOL-settled) | Residual common equity |
|---|
| $73 (≈ today) | ~$163M | −$57M | −$181M | ≈ −$75M (equity underwater) |
| $150 (≈ cost basis) | ~$335M | −$57M | −$181M | $97M ($1.38/sh on 70M) |
| $293 (prior cycle high) | ~$655M | −$57M | −$181M (likely converts to equity ≫ strike → dilution instead) | ~$200M+ pre-dilution; converts flip to ~50M new shares |
Base / bull / bear (12–18 month, equity value):
- Base: SOL rangebound ~$70–110. Equity hovers around/just-above zero intrinsic; UPXI trades as a distressed 0.5–0.8x-NAV option on SOL. Continuous ATM dilution erodes tokens-per-share. Target equity value
$40–80M ($0.55–$1.10/sh) — below to around today's ~$64M cap; net flat-to-down.
- Bull: SOL re-rates to >$150 (toward cost basis). Equity intrinsic turns positive, mNAV can re-expand toward 1x, and the converts ($4.25/$2.39) come into play as equity (dilutive but solvency-positive). UPXI is a high-beta call — could multi-bag off a $0.91 base. This is the only case the bulls own.
- Bear: SOL <$60 → BitGo 175% margin call forces SOL sales into weakness; the SOL-repayable converts mean bondholders' ~1.23M-SOL claim exceeds the liquid token stack; book equity deeply negative; ATM access dries up at a sub-$1 stock. Plausible path to ~zero equity / restructuring.
The Brier-able binary (for /thesis, not logged here): "SOL ≥ $73 at the July-16-2027 convert maturity" — below it, the equity is structurally a stub.
Lens 12 · Bull vs Bear
Bull case. (1) Cheapest levered SOL in a wrapper — at ~0.7x NAV and ~$0.91, UPXI is a high-beta call option on a Solana recovery; a move back to even cost-basis SOL ($150) flips the equity from underwater to ~$1.40+ intrinsic. (2) Real management pedigree (Marshall built XPO) and a crypto-native CSO ex-GSR/Citadel. (3) ~95% staked at ~7% plus discounted locked-SOL accretion is a genuine, if small, yield engine. (4) Optionality: the Alpha City Exchange royalty (14.9% of gross revenue, scaling to 19.9%) is a free call on a SOL-DeFi venue. (5) Most of the loss is non-cash marks, not operating cash destruction.
Bear case (the base). (1) Negative book equity + SOL-repayable debt = the equity is a residual claim behind ~1.23M SOL owed to bondholders; this is not the same as owning SOL — it's owning the levered, subordinated stub. (2) mNAV < 1x kills the only moat — issuing equity now destroys tokens-per-share, so the compounding story is dead and the ATM is pure dilution. (3) Margin-call reflexivity — a 175% trip-wire on the BitGo facility can force selling into the exact weakness that triggers it. (4) Governance: super-voting founder control, dense related-party dealings, comp tied to treasury growth/market-cap, a blown-up 20-year asset-manager contract now in arbitration, and unremediated material weaknesses. (5) The operating business is being euthanized — no independent cash engine to defend the equity.
Pre-mortem (18 months out, thesis broke): SOL drifted to $55–65; the BitGo facility hit its margin level and Upexi was forced to sell liquid SOL, shrinking the stack below the bondholders' in-kind claim; the sub-$1 stock couldn't support further ATM issuance; a going-concern qualification appeared; the equity went to a fraction of NAV or to a restructuring. The "adjusted SOL per share" PRs aged badly.
Are multiples too high? "Multiple" is NAV-relative. At 0.7x basic mNAV the headline looks cheap, but adjusting for the SOL-repayable converts and the margin facility, the economic claim of the common is far thinner than 0.7x of gross treasury — arguably the equity is fairly priced or rich for the leverage it carries.
Contrarian view (what the market may be missing, either way): the bull contrarian take is that all SOL DATs are being tarred with the same 0.6–0.7x brush, so a SOL recovery + the converts flipping to equity could un-lever Upexi violently and re-rate it faster than peers. The bear contrarian take — which I weight more heavily — is that the market is under-pricing the SOL-settlement feature: investors model UPXI as "0.7x of $185M of SOL" when bondholders actually own the first ~$181M of it, leaving common-holders a deeply-subordinated, margin-callable stub that the 0.7x optic flatters.
Lens 13 · Devil's Advocate (short-seller)
Dismantling the bull case.
- "It's cheap SOL at 0.7x NAV." No — it's the levered residual behind SOL-repayable debt. The honest look-through: ~2.36M SOL, but ~1.23M is owed to convert holders in kind and ~$57M to a margin lender. Common-holders own a thin, junior slice that goes negative below ~$75–90 SOL. The 0.7x figure is the single most misleading number in the story.
- Concentration: 100% one token, explicitly unhedged, with a 175% margin-call mechanic — the textbook setup for a forced-seller death spiral in a drawdown.
- The moat is inverted: below NAV, the DAT flywheel runs backwards; every ATM share sold (another ~$4.5M in Apr–May 2026) dilutes tokens-per-share. The "adjusted SOL per share" metric adjusts out leverage — the very thing that will destroy holders if SOL falls. That's a marketing instrument.
- Most dangerous competitor: DFDV — larger SOL stack, ex-Kraken team, was the 853% 2025 winner, $100M buyback — and it still trades ~0.6x NAV. If the best-capitalized SOL DAT can't hold a premium, the sub-scale, negative-equity one has no path to one.
- Worst capital-allocation / governance: accumulating SOL at ~$151–160 near the top with SOL-repayable leverage; a 20-year, 1.75%-AUM, 5x-or-$15M-termination-fee asset-management contract with GSR (the same firm that led the PIPE and supplied the CSO) that blew up into arbitration in ~8 months; super-voting founder preferred; comp tied to treasury growth and market cap; material weaknesses in controls; $18M SBC on $7M of product revenue.
- What must hold for today's price: continuous capital-market access and a SOL price that stays above the level where the BitGo facility margin-calls and where the SOL-settled converts don't exceed the liquid token stack. Several of those are correlated and break together.
- −20–30% growth/price shock: a 25% further SOL fall (to ~$55) likely triggers the margin mechanic and pushes the common toward zero intrinsic.
- The single scenario that permanently impairs: a sustained SOL bear (sub-$60) that forces SOL sales below the bondholders' in-kind claim while the sub-$1 equity is shut out of the ATM → restructuring. Plausibility: moderate and rising given SOL is already ~$73 and the company has $3.5M cash.
Lens 14 · Management Questions (ordered by information value)
- At today's mNAV below 1x, why issue any equity via the ATM — doesn't every share sold below NAV mechanically dilute SOL-per-share? What is your hard mNAV floor below which you halt issuance?
- The July-2025 and Jan-2026 converts are repayable in ~1.23M SOL if not converted. At a sub-$4.25 / sub-$2.39 stock, you should assume SOL settlement — how do you repay ~52% of your treasury to bondholders in 2027–2028 without gutting the stack?
- What are the exact current collateral coverage and the 175% margin-call level on the BitGo Prime facility today at SOL ~$73, and what SOL price forces a sale?
- You hold 100% SOL, explicitly unhedged. Why no downside hedge (puts/collars) on a balance sheet that is now your entire enterprise?
- Walk through the GSR arbitration: what is GSR's counterclaim quantum, what is your maximum exposure, and could the $15M/5x termination-fee provision attach?
- Your disclosure controls are "not effective" with two material weaknesses — for a company valued off a single oracle-priced asset, what is the remediation timeline and who is accountable?
- The CEO bought a subsidiary (VitaMedica) from the company, leases it a warehouse, and holds super-voting preferred. How does the board defend this related-party stack to minority holders?
- CEO comp is tied to "market cap / treasury growth." Isn't that a direct incentive to dilute below NAV to grow the SOL count? Will you re-anchor it to SOL-per-share net of debt?
- Define "adjusted SOL per share" precisely and reconcile it to basic SOL per share — why is adjusting out leverage the right lens for a levered vehicle?
- With $3.5M cash and −$17M/9M operating burn, what is your runway absent further capital raises, and what is the trigger for a going-concern assessment?
- What is the realistic revenue and cash contribution of the products remnant now that manufacturing is shut and distribution is outsourced — or should investors model it at zero?
- The Alpha City Exchange royalty ($750K for 14.9% of gross revenue): what is the platform's user count and revenue today, and what are the milestone triggers actually worth?
- What is the blended cost basis of the treasury today, and at what SOL price does consolidated book equity return to positive?
- The locked-SOL 14% discount is a management estimate on ~40% of the treasury. Who validates it, and how would a wider discount affect covenant/collateral calculations?
- Under what concrete conditions would the board conclude the DAT structure has failed and return to operating, wind down the leverage, or pursue a sale?